28 related articles for article (PubMed ID: 38458396)
1. An Essential Membrane Protein Modulates the Proteolysis of LpxC to Control Lipopolysaccharide Synthesis in Escherichia coli.
Fivenson EM; Bernhardt TG
mBio; 2020 May; 11(3):. PubMed ID: 32430473
[TBL] [Abstract][Full Text] [Related]
2. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.
Mdluli KE; Witte PR; Kline T; Barb AW; Erwin AL; Mansfield BE; McClerren AL; Pirrung MC; Tumey LN; Warrener P; Raetz CR; Stover CK
Antimicrob Agents Chemother; 2006 Jun; 50(6):2178-84. PubMed ID: 16723580
[TBL] [Abstract][Full Text] [Related]
3. Control of lipopolysaccharide biosynthesis by FtsH-mediated proteolysis of LpxC is conserved in enterobacteria but not in all gram-negative bacteria.
Langklotz S; Schäkermann M; Narberhaus F
J Bacteriol; 2011 Mar; 193(5):1090-7. PubMed ID: 21193611
[TBL] [Abstract][Full Text] [Related]
4. YejM Controls LpxC Levels by Regulating Protease Activity of the FtsH/YciM Complex of Escherichia coli.
Nguyen D; Kelly K; Qiu N; Misra R
J Bacteriol; 2020 Aug; 202(18):. PubMed ID: 32540932
[TBL] [Abstract][Full Text] [Related]
5. Common and varied molecular responses of Escherichia coli to five different inhibitors of the lipopolysaccharide biosynthetic enzyme LpxC.
Möller AM; Vázquez-Hernández M; Kutscher B; Brysch R; Brückner S; Marino EC; Kleetz J; Senges CHR; Schäkermann S; Bandow JE; Narberhaus F
J Biol Chem; 2024 Apr; 300(4):107143. PubMed ID: 38458396
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.
Erwin AL
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27235477
[TBL] [Abstract][Full Text] [Related]
7. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
Zhou P; Hong J
Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
[TBL] [Abstract][Full Text] [Related]
8. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
[TBL] [Abstract][Full Text] [Related]
9. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
Liu F; Ma S
Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
[TBL] [Abstract][Full Text] [Related]
10. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
Zhang J; Zhang L; Li X; Xu W
Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
[TBL] [Abstract][Full Text] [Related]
11. LpxC inhibitors: a patent review (2010-2016).
Kalinin DV; Holl R
Expert Opin Ther Pat; 2017 Nov; 27(11):1227-1250. PubMed ID: 28742403
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
